Mologen AG Acquires Innovative Technology

The Berlin-based biotechnology company MOLOGEN announced today that it has concluded an agreement with Netherlands based Synvolux Therapeutics B.V. ("Synvolux") regarding the use of the SAINT technology developed by Synvolux.
MORE ON THIS TOPIC